retatrutide vs mounjaro Mounjaro: triple agonist versus dual agonist compared Retatrutide vs Wegovy vs Mounjaro

Description

Multivitamins, protein shakes, and gut health aids to address muscle loss, nutrient gaps, and digestive issues.

The $10 billion price tag, the bidding war with Novo Nordisk, the lawsuits, it all made for high drama

GLP-1 supplements vary widely in efficacy and safety

Newer GLP-1 therapies are redefining whats possible in medical weight loss. Retatrutide is a next-generation triple-agonist GLP-1...

Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution